EGFR and non-small cell lung carcinoma: Taken together, these results suggest that oncogenic miRNA loading partially contributes to EGFR‐TKI resistance, and the combination therapy with Amlexanox represents a particularly potent approach to overcome EGFR‐TKI resistance of NSCLC.